机构地区:[1]State Key Laboratory of Cell Biology,Chinese Academy of Sciences,Shanghai 200031,China [2]Shanghai Institute of Biochemistry and Cell Biology,Chinese Academy of Sciences,Shanghai 200031,China [3]Center for Excellence in Molecular Cell Science,Chinese Academy of Sciences,Shanghai 200031,China [4]Center for Excellence in Mathematical Sciences,National Center for Mathematics and Interdisciplinary Sciences,Key Laboratory of Management,Decision and Information System,Hua Loo-Keng Center for Mathematical Sciences,Academy of Mathematics and Systems Science,Chinese Academy of Sciences,Beijing 100190,China [5]Shenzhen Key Laboratory of Translational Medicine of Tumor,Department of Cell Biology and Genetics,Shenzhen University Health Sciences Center,Shenzhen 518060,China [6]Shanghai Pulmonary Hospital,Tongji University,Shanghai 200092,China [7]Shanghai Chest Hospital,Shanghai Jiaotong University,Shanghai 200030,China [8]Zhongshan Hospital,Fudan University,Shanghai 200032,China [9]Department of Pathology,School of Basic Medical Sciences,Fudan University,Shanghai 200032,China [10]School of Life Science and Technology,Shanghai Tech University,Shanghai 200120,China [11]CAS Key Laboratory of Tissue Microenvironment and Tumor,CAS Center for Excellence in Molecular Cell Science,Shanghai Institute of Nutrition and Health Sciences,Chinese Academy of Sciences,Shanghai 200031,China [12]Laura and Isaac Perlmutter Cancer Center,New York University Langone Medical Center,New York,NY 10016,USA [13]Department of Translational Genomics,Center of Integrated Oncology Cologne-Bonn,Medical Faculty,University of Cologne,Cologne 50931,Germany [14]School of Life Science,Hangzhou Institute for Advanced Study,University of Chinese Academy of Sciences,Hangzhou 310024,China [15]Department of Pathology,University Hospital Cologne,Cologne 50937,Germany
出 处:《National Science Review》2022年第7期10-24,共15页国家科学评论(英文版)
基 金:the National Natural Science Foundation of China(81871875 and 82173340 to L.H.,82030083,81872312,82011540007 and 31621003 to H.J.,81402371 to Y.J.,12025107 to Y.W.);the National Basic Research Program of China(2017YFA0505501 and 2020YFA0803300 to H.J.);the Strategic Priority Research Program of the Chinese Academy of Sciences(XDB19020201 to H.J.);the Basic Frontier Scientific Research Program of the Chinese Academy of Sciences(ZDBSLY-SM006 to H.J.);the International Cooperation Project of the Chinese Academy of Sciences(153D31KYSB20190035 to H.J.);the Innovative Research Team of High-Level Local Universities in Shanghai(SSMU-ZLCX20180500 to H.J.);the Science and Technology Commission of Shanghai Municipality(21ZR1470300 to L.H.).
摘 要:Small-cell lung cancer(SCLC)is a recalcitrant cancer characterized by high metastasis.However,the exact cell type contributing to metastasis remains elusive.Using a Rb1^(L/L)/Trp53^(L/L) mouse model,we identify the NCAM^(hi)CD44^(lo/–) subpopulation as the SCLC metastasizing cell(SMC),which is progressively transitioned from the non-metastasizing NCAM^(lo)CD44^(hi) cell(non-SMC).Integrative chromatin accessibility and gene expression profiling studies reveal the important role of the SWI/SNF complex,and knockout of its central component,Brg1,significantly inhibits such phenotypic transition and metastasis.Mechanistically,TAZ is silenced by the SWI/SNF complex during SCLC malignant progression,and its knockdown promotes SMC transition and metastasis.Importantly,ectopic TAZ expression reversely drives SMC-to-non-SMC transition and alleviates metastasis.Single-cell RNA-sequencing analyses identify SMC as the dominant subpopulation in human SCLC metastasis,and immunostaining data show a positive correlation between TAZ and patient prognosis.These data uncover high SCLC plasticity and identify TAZ as the key molecular switch in orchestrating SCLC phenotypic transition and metastasis.
关 键 词:small cell lung cancer SWI/SNF complex TAZ phenotypic transition METASTASIS
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...